Texas State University Acquires Rigaku SCXmini Chemical Crystallography Instrument
News Jan 08, 2009
Rigaku Americas Corporation has announced that the Department of Chemistry and Biochemistry at the Texas State University has purchased a Rigaku SCXmini™ benchtop small molecule X-ray diffraction (XRD) crystallography instrument for Cyber-enabled Small Molecule Structure Analysis for Research and Educational Purposes as funded by a Major Research Instrumentation program (MRI) grant from the National Science Foundation (NSF).
A Rigaku SCXmini™ X-ray crystallography system was chosen by Prof. Benjamin Martin (Principal Investigator), Prof. Gary Beall (co-PI), Prof. Michael Blanda (Co-PI), and Prof. Debra Feakes (Co-PI) to enhance the X-ray facilities of the Department of Chemistry and Biochemistry in support of education and research at Texas State and a consortium of "cyber-enabled" collaborators from Lamar University, San Antonio College, Texas Lutheran University and Sam Houston State University.
The SCXmini™ X-ray diffractometer will be employed to strengthen research endeavors and spark new explorations in areas involving: sulfide and selenide materials, solid state linkage isomerism and ligand substitution in transition metal cyanide complexes, conformational isomers of immobilized calixarenes, polyhedral borane anions, sulfido-bridged iron compounds and magnetostructural studies of Ni(II) dimers, and the preparation of titanium complexes as well as a variety of other research topics.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE